세계의 구속성 펩타이드 의약품 시장 : 시장 규모 - 용도별, 유형별, 지역별, 예측(2022-2032년)

The Global Constrained Peptide Drugs Market is valued at approximately USD 1.24 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 15.00% over the forecast period 2024-2032. Constrained peptide drugs are produced using peptides with short amino chains and are characterized by their supermolecular structure controlled through intramolecular covalent bonds. These peptides are developed to impart superior physicochemical and biochemical properties compared to traditional counterparts, making them highly versatile in various end-use applications. These drugs are designed with structural constraints, such as cyclization or the incorporation of non-natural amino acids, to enhance their stability, bioavailability, and binding affinity to target molecules. The structural constraints prevent the peptides from rapidly degrading or being cleared from the body, thereby improving their therapeutic efficacy and specificity.

The constrained peptide drugs market is being driven by several factors such as rising prevalence of chronic diseases such as cancer, metabolic disorders, and autoimmune diseases necessitates the development of more effective and targeted treatments, for which constrained peptides are well-suited due to their high specificity and potency. Moreover, advancements in peptide synthesis and design technologies are enabling the creation of more stable and potent peptide drugs, thereby expanding their therapeutic potential and application range. Additionally, increased investment in biopharmaceutical research and development by both public and private sectors is accelerating the discovery and commercialization of constrained peptide drugs. This is complemented by a favorable regulatory environment, particularly in regions like North America and Europe, which facilitates faster approval and market entry for innovative peptide therapeutics.

Moreover, collaborations between pharmaceutical companies and academic institutions are fostering innovation and the development of new peptide-based therapies. These partnerships often lead to breakthroughs in drug design and delivery mechanisms, further propelling market growth. However, the market also faces challenges such as high production costs and complex manufacturing processes associated with constrained peptides and competition from existing small-molecule drugs and biologics, as well as high investment costs for development and commercial distribution.

The key regions considered in the study include Asia Pacific, North America, Europe, Latin America, and the Middle East and Africa. North America dominates the global constrained peptide drugs market and is also the fastest-growing region in this sector. Several factors drive this dominance and rapid growth. North America, particularly the United States, has a robust biopharmaceutical industry characterized by substantial investment in research and development, advanced healthcare infrastructure, and a strong focus on innovation. Additionally, the region benefits from favorable regulatory frameworks and expedited approval processes for innovative treatments by agencies such as the U.S. Food and Drug Administration (FDA). High prevalence of chronic diseases, including cancer, diabetes, and cardiovascular disorders, increases the demand for effective and targeted therapies. Constrained peptide drugs, known for their specificity and potency, are increasingly sought after to address these medical conditions. Moreover, North America's strong network of academic and research institutions contributes to ongoing advancements in peptide drug research, fostering collaboration between academia and industry. Lastly, significant government and private funding for healthcare research and the presence of venture capital investments in biotech startups further support market growth.

Major market players included in this report are:

• Union Chimique Belge S.A. (UCB)
• Aileron Therapeutics Inc.
• Zealand Pharma
• Bio-Synthesis Inc.
• Spexis AG
• Bicycle Therapeutics plc
• Circle Pharma
• Creative Peptides
• PeptiDream Inc.
• Pepticom Ltd.
• Protagonist Therapeutics Inc.
• Chugai Pharmaceutical Co. Ltd.
• Biosynth (Pepscan)
• Santhera Pharmaceuticals
• CPC Scientific Inc.

The detailed segments and sub-segment of the market are explained below:

By Application:

• Institutes of Biology
• Hospitals

By Type:

• Disulfide-Rich Peptides (DRPs)
• Cyclic Peptides

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Italy
• Spain
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• RoAPAC
• Latin America
• Brazil
• Mexico
• RoLA
• Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Constrained Peptide Drugs Market Executive Summary

• 1.1. Global Constrained Peptide Drugs Market Size & Forecast (2022-2032)
• 1.2. Regional Summary
• 1.3. Segmental Summary
  • 1.3.1. By Application
  • 1.3.2. By Type
• 1.4. Key Trends
• 1.5. Recession Impact
• 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Constrained Peptide Drugs Market Definition and Research Assumptions

• 2.1. Research Objective
• 2.2. Market Definition
• 2.3. Research Assumptions
  • 2.3.1. Inclusion & Exclusion
  • 2.3.2. Limitations
  • 2.3.3. Supply Side Analysis
    • 2.3.3.1. Availability
    • 2.3.3.2. Infrastructure
    • 2.3.3.3. Regulatory Environment
    • 2.3.3.4. Market Competition
    • 2.3.3.5. Economic Viability (Consumer's Perspective)
  • 2.3.4. Demand Side Analysis
    • 2.3.4.1. Regulatory frameworks
    • 2.3.4.2. Technological Advancements
    • 2.3.4.3. Environmental Considerations
    • 2.3.4.4. Consumer Awareness & Acceptance
• 2.4. Estimation Methodology
• 2.5. Years Considered for the Study
• 2.6. Currency Conversion Rates

Chapter 3. Global Constrained Peptide Drugs Market Dynamics

• 3.1. Market Drivers
  • 3.1.1. Growing Investments in Novel Drug Research and Development
  • 3.1.2. Increased Focus on Developing Effective Treatments for Fatal Diseases
  • 3.1.3. Rising Cancer Cases Promoting Higher Research
• 3.2. Market Challenges
  • 3.2.1. Nascent Stage of the Industry
  • 3.2.2. High Cost of Investment
  • 3.2.3. Lack of Infrastructure for Development
• 3.3. Market Opportunities
  • 3.3.1. Increase in Access to Medical Care Worldwide
  • 3.3.2. Surging Demand for Personalized Medical Care
  • 3.3.3. Growth in Telemedicine and Advanced Technologies

Chapter 4. Global Constrained Peptide Drugs Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's 5 Force Model
  • 4.1.7. Porter's 5 Force Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economical
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top investment opportunity
• 4.4. Top winning strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Constrained Peptide Drugs Market Size & Forecasts by Application 2022-2032

• 5.1. Segment Dashboard
• 5.2. Global Constrained Peptide Drugs Market: Application Revenue Trend Analysis, 2024 & 2032 (USD Billion)
  • 5.2.1. Institutes of Biology
  • 5.2.2. Hospitals

Chapter 6. Global Constrained Peptide Drugs Market Size & Forecasts by Type 2022-2032

• 6.1. Segment Dashboard
• 6.2. Global Constrained Peptide Drugs Market: Type Revenue Trend Analysis, 2024 & 2032 (USD Billion)
  • 6.2.1. Disulfide-Rich Peptides (DRPs)
  • 6.2.2. Cyclic Peptides

Chapter 7. Global Constrained Peptide Drugs Market Size & Forecasts by Region 2022-2032

• 7.1. North America Constrained Peptide Drugs Market
  • 7.1.1. U.S. Constrained Peptide Drugs Market
    • 7.1.1.1. Application breakdown size & forecasts, 2022-2032
    • 7.1.1.2. Type breakdown size & forecasts, 2022-2032
  • 7.1.2. Canada Constrained Peptide Drugs Market
• 7.2. Europe Constrained Peptide Drugs Market
  • 7.2.1. UK Constrained Peptide Drugs Market
  • 7.2.2. Germany Constrained Peptide Drugs Market
  • 7.2.3. France Constrained Peptide Drugs Market
  • 7.2.4. Italy Constrained Peptide Drugs Market
  • 7.2.5. Spain Constrained Peptide Drugs Market
  • 7.2.6. Rest of Europe Constrained Peptide Drugs Market
• 7.3. Asia Pacific Constrained Peptide Drugs Market
  • 7.3.1. China Constrained Peptide Drugs Market
  • 7.3.2. India Constrained Peptide Drugs Market
  • 7.3.3. Japan Constrained Peptide Drugs Market
  • 7.3.4. Australia Constrained Peptide Drugs Market
  • 7.3.5. South Korea Constrained Peptide Drugs Market
  • 7.3.6. Rest of Asia Pacific Constrained Peptide Drugs Market
  • 7.4.1. Latin America Constrained Peptide Drugs Market
    • 7.4.1.1. Brazil Constrained Peptide Drugs Market
    • 7.4.1.2. Mexico Constrained Peptide Drugs Market
    • 7.4.1.3. Rest of Latin America Constrained Peptide Drugs Market
  • 7.4.2. Middle East & Africa Constrained Peptide Drugs Market
    • 7.4.2.1. Saudi Arabia Countries Constrained Peptide Drugs Market
    • 7.4.2.2. South Africa Constrained Peptide Drugs Market
    • 7.4.2.3. Rest of Middle East & Africa Constrained Peptide Drugs Market

Chapter 8. Competitive Intelligence

• 8.1. Key Company SWOT Analysis
  • 8.1.1. Company 1
• 8.2. Top Market Strategies
• 8.3. Company Profiles
  • 8.3.1. Aileron Therapeutics, Inc.
    • 8.3.1.1. Key Information
    • 8.3.1.2. Overview
    • 8.3.1.3. Financial (Subject to Data Availability)
    • 8.3.1.4. Product Summary
    • 8.3.1.5. Market Strategies
  • 8.3.2. Bicycle Therapeutics plc
  • 8.3.3. Protagonist Therapeutics Inc.
  • 8.3.4. Santhera Pharmaceuticals
  • 8.3.5. Union Chimique Belge S.A. (UCB)
  • 8.3.6. Creative Peptides
  • 8.3.7. Biosynth (Pepscan)
  • 8.3.8. Pepticom Ltd.
  • 8.3.9. PeptiDream Inc.
  • 8.3.10. Bio-Synthesis Inc.
  • 8.3.11. CPC Scientific Inc.
  • 8.3.12. Circle Pharma
  • 8.3.13. Zealand Pharma
  • 8.3.14. Chugai Pharmaceutical Co. Ltd.
  • 8.3.15. Spexis AG

Chapter 9. Research Process

• 9.1. Research Process
  • 9.1.1. Data Mining
  • 9.1.2. Analysis
  • 9.1.3. Market Estimation
  • 9.1.4. Validation
  • 9.1.5. Publishing
• 9.2. Research Attributes